Electrogram prolongation and nifedipine-suppressible ventricular arrhythmias in mice following targeted disruption of KCNE1

Journal of Physiology

Volumn 552, Issue 2, 2003, Pages 535-546

  Balasubramaniam, Richard ^a   Grace, Andrew A ^a   Saumarez, Richard C ^a   Vandenberg, Jamie I ^b   Huang, Christopher L H ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INWARDLY RECTIFYING POTASSIUM CHANNEL; ISOPRENALINE; NIFEDIPINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNE1;

ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; ELECTROGRAPHY; ELECTROSTIMULATION; EPICARDIUM; GENE DELETION; GENE DISRUPTION; GENE MUTATION; GENE TARGETING; HEART CONDUCTION; HEART LEFT VENTRICLE; HEART PACING; HEART PERFORMANCE; HEART VENTRICLE ARRHYTHMIA; HOMOZYGOSITY; LONG QT SYNDROME; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; WAVEFORM; WILD TYPE; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; FEMALE; HEART RIGHT VENTRICLE; ISOLATED HEART; MALE; PROTEIN DEFECT; WILD TYPE MOUSE;

ADRENERGIC BETA-AGONISTS; ANIMALS; ARRHYTHMIA; CALCIUM CHANNEL BLOCKERS; CARDIAC PACING, ARTIFICIAL; ELECTRIC STIMULATION; ELECTROCARDIOGRAPHY; ELECTRODES, IMPLANTED; ELECTROPHYSIOLOGY; ISOPROTERENOL; MICE; MICE, KNOCKOUT; NIFEDIPINE; PATCH-CLAMP TECHNIQUES; PHENOTYPE; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED;

EID: 0142150032     PISSN: 00223751     EISSN: None     Source Type: Journal    
DOI: 10.1113/jphysiol.2003.048249     Document Type: Article

References (50)

1. Antzelevitch C & Shimizu W (2002). Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol 17, 43-51.
2. Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M & Romey G (1996). K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature 384, 78-80.
3. + currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res 73, 379-385.
4. Bhandari AK, Shapiro WA, Morady F, Shen EN, Mason J & Scheinman MM (1985). Electrophysiologic testing in patients with the long QT syndrome. Circulation 71, 63-71.
5. Casimiro MC, Knollmann BC, Ebert SN, Vary JC Jr, Greene AE, Franz MR, Grinberg A, Huang SP & Pfeifer K (2001). Targeted disruption of the Kcnq1 gene produces a mouse model of Jervell and Lange-Nielsen Syndrome. Proc Natl Acad Sci U S A 98, 2526-2531.
6. + channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol 54, 695-703.
7. Cosio FG, Goicolea A, Lopez Gil M, Kallmeyer C & Barroso JL (1991). Suppression of Torsades de Pointes with verapamil in patients with atrio-ventricular block. Eur Heart J 12, 635-638.
8. Demolombe S, Lande G, Charpentier F, van Roon MA, van den Hoff MJ, Toumaniantz G, Baro I, Guihard G, Le Berre N, Corbier A, De Bakker J, Opthof T, Wilde A, Moorman AF & Escande D (2001). Transgenic mice overexpressing human KvLQT1 dommant-negative isoform. Part I: phenotypic characterisation. Cardiovasc Res 50, 314-327.
9. + channel in heart rate control of repolarization in a murine engineered model of Jervell and Lange-Nielsen syndrome. Circ Res 83, 95-102.
10. Duggal P, Vesely MR, Wattanasirichaigoon D, Villafane J, Kaushik V & Beggs AH (1998). Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of Long-QT syndrome. Circulation 97, 142-146.
11. el-Sherif N, Caref EB, Yin H & Restivo M (1996). The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns. Circ Res 79, 474-492.
12. Hohnloser SH, Klingenheben T & Singh BN (1994). Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 121, 529-535.
13. Keating MT & Sanguinetti MC (2001). Molecular and cellular mechanisms of cardiac arrhythmias. Cell 104, 569-580.
14. Kupershmidt S, Yang T, Anderson ME, Wessels A, Niswender KD, Magnuson MA & Roden DM (1999). Replacement by homologous recombination of the minK gene with lacZ reveals restriction of min K expression to the mouse cardiac conduction system. Circ Res 84, 146-152.
15. Langendorff O (1895). Untersuchungen am überlebenden Säugethierherzen. Pflugers Arch ges Physiol 61, 291-332.
16. Lee MP, Ravenel JD, Hu RJ, Lustig LR, Tomaselli G, Berger RD, Brandenburg SA, Litzi TJ, Bunton TE, Limb C, Francis H, Gorelikow M, Gu H, Washington K, Argani P, Goldenring JR, Coffey RJ & Feinberg AP (2000). Targeted disruption of the Kvlqt1 gene causes deafness and gastric hyperplasia in mice. J Clin Invest 106, 1447-1455.
17. Levine JH, Spear JF, Guarnieri T, Weisfeldt ML, de Langen CD, Becker LC & Moore EN (1985). Cesium chloride-induced long QT syndrome: demonstration of afterdepolarizations and triggered activity in vivo. Circulation 72, 1092-1103.
18. Marban E (2002). Cardiac channelopathies. Nature 415, 213-218.
19. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, Vincent GM, Locati EH, Priori SG, Napolitano C, Medina A, Zhang L, Robinson JL, Timothy K, Towbin JA & Andrews ML (2000). Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 101, 616-623.
20. Neyroud N, Maison-Blanche P, Denjoy I, Chevret S, Donger C, Dausse E, Fayn J, Badilini F, Menhabi N, Schwartz K, Guicheney P & Coumel P (1998). Diagnostic performance of QT interval variables from 24-h electrocardiography in the long QT syndrome. Eur Heart J 19, 158-165.
21. Noble D (1992). Ionic mechanisms determining the timing of ventricular repolarization: significance for cardiac arrhythmias. Ann N Y Acad Sci 644, 1-22.
22. O'Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberg GW, Frid DJ, Cropp AB, Anderson S, Wertheimer JH & Demets DL (1998). Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol 82, 881-887.
23. Packer M (1990). Calcium channel blockers in chronic heart failure. The risks of 'physiologically rational' therapy. Circulation 82, 2254-2257.
24. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB & Demets DL (1996). Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 335, 1107-1114.
25. Papadatos GA, Wallerstein PM, Head CE, Ratcliff R, Brady PA, Benndorf K, Saumarez RC, Trezise AE, Huang CL, Vandenberg JI, Colledge WH & Grace AA (2002). Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. Proc Natl Acad Sci U S A 99, 6210-6215.
26. Roden DM & Anderson ME (2000). The pause that refreshes, or does it? Mechanisms in torsades de pointes. Heart 84, 235-237.
27. Roden DM, Balser JR, George AL Jr & Anderson ME (2002). Cardiac ion channels. Annu Rev Physiol 64, 431-475.
28. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL & Keating MT (1996). Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 384, 80-83.
29. Saumarez RC, Chojnowska L, Derksen R, Pytkowski M, Sterlinski M, Huang CL, Sadoul N, Hauer RN, Ruzyllo W & Grace AA (2003). Sudden death in non-coronary heart disease is associated with delayed paced ventricular activation. Circulation 107, 2595-2600.
30. Saumarez RC & Grace AA (2000). Paced ventricular electrogram fractionation and sudden death in hypertrophic cardiomyopathy and other non-coronary heart diseases. Cardiovasc Res 47, 11-22.
31. Schulze-Bahr E, Wang Q, Wedekind H, Haverkamp W, Chen Q, Sun Y, Rubie C, Hordt M, Towbin JA, Borggrefe M, Assmann G, Qu X, Somberg JC, Breithardt G, Oberti C & Funke H (1997). KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. Nat Genet 17, 267-268.
32. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P & Bloise R (2001). Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 103, 89-95.
33. Shimizu W & Antzelevitch C (2000a). Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 35, 778-786.
34. Shimizu W & Antzelevitch C (2000b). Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1; LQT2, and LQT3 models of the long-QT syndrome. Circulation 102, 706-712.
35. + channel opener in the LQT1 form of congenital long-QT syndrome. Circulation 97, 1581-1588.
36. Shimizu W, Ohe T, Kurita T, Kawade M, Arakaki Y, Aihara N, Kamakura S, Kamiya T & Shimomura K (1995). Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol 26, 1299-1309.
37. Shimizu W, Ohe T, Kurita T, Takaki H, Aihara N, Kamakura S, Matsuhisa M & Shimomura K (199 1). Early afterdepolarizations induced by isoproterenol in patients with congenital long QT syndrome. Circulation 84, 1915-1923.
38. Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC & Keating MT (1997). Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet 17, 338-340.
39. Thackray S, Witte K, Clark AL & Cleland JG (2000). Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail 2, 209-212.
40. Tomaselli GF, Beuckelmann DJ, Calkins HG, Berger RD, Kessler PD, Lawrence JH, Kass D, Feldman AM & Marban E (1994). Sudden cardiac death in heart failure. The role of abnormal repolarization. Circulation 90, 2534-2539.
41. Tomaselli GF & Marban E (1999). Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 42, 270-283.
42. Vetter DE, Mann JR, Wangemann P, Liu J, McLaughlin KJ, Lesage F, Marcus DC, Lazdunski M, Heinemann SF & Barhanin J (1996). Inner ear defects induced by null mutation of the isk gene. Neuron 17, 1251-1264.
43. Waldo AL, Camm AJ, Deruyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ & Veltri EP (1996). Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral D-Sotalol. Lancet 348, 7-12.
44. + channels in mouse heart. Circ Res 79, 79-85.
45. Warth R & Barhanin J (2002). The multifaceted phenotype of the knockout mouse for the KCNE1 potassium channel gene. Am J Physiol Regul Integr Comp Physiol 282, R639-648.
46. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL Jr & Roden DM (2002). Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105, 1943-1948.
47. Yazawa K & Kameyama M (1990). Mechanism of receptor-mediated modulation of the delayed outward potassium current in guinea-pig ventricular myocytes. J Physiol 421, 135-150.
48. Zhang S, Zhou Z, Gong Q, Makielski JC & January CT (1999). Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84, 989-998.
49. Zheng ZJ, Croft JB, Giles WH & Mensah GA (2001). Sudden cardiac death in the United States, 1989 to 1998. Circulation 104, 2158-2163.
50. Zipes DP & Wellens HJ (1998). Sudden cardiac death. Circulation 98, 2334-2351.